Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports-March 2024-www.financetom.com

Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports

May 28, 2024 6:41 PM

May 28 (Reuters) - Merck & Co ( MRK ) is nearing a $1.3

billion cash deal to buy ophthalmology biotechnology company

Eyebiotech in an agreement that could see an additional $1.7

billion in milestone payments, the Wall Street Journal reported

on Tuesday.

(Reporting by Kanjyik Ghosh; Editing by Subhranshu Sahu)

Previous page： A Manimekhalai to be first woman MD & CEO at Union Bank of India Next page： Centre mandates companies to seek nod before appointing citizens from border nations as directors

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

A Manimekhalai to be first woman MD & CEO at Union Bank of India

Jun 3, 2022

Currently the executive director of Canara Bank, Manimekhalai is a seasoned banker with more than three decades' experience. She started her career with erstwhile Vijaya Bank.

Centre mandates companies to seek nod before appointing citizens from border nations as directors

Jun 4, 2022

Experts say the change has been especially made keeping China in mind.Till February this year, 490 foreign nationals were registered as active directors in India.

Sun Pharma to increase field force in India by 10% this fiscal year

Jun 5, 2022

Sun Pharma's India formulations sales for the full year FY22 stood at Rs 12,759 crore recording a strong 23 percent growth over 2020-21 fiscal.

In midst of transformation; addressing weaknesses in ops and product portfolio: Eveready MD

Jun 4, 2022

"Despite the results, I sincerely believe that the company is now on a journey towards the higher reaches and is in the midst of a transformation that provides the road map. The company has now taken steps to address areas of weaknesses in its operations and the product portfolio," managing director Suvamoy Saha said.